Graft-versus-host disease future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are a few new investigational efforts in place for GvHD | There are a few new investigational efforts in place for GvHD prevention, diagnostics, and therapeutics. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
*Regarding prevention, studies have shown that Aurora kinase may be a targetable pathway to prevent GvHD.<ref name="pmid26606970">{{cite journal| author=Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S et al.| title=Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. | journal=Sci Transl Med | year= 2015 | volume= 7 | issue= 315 | pages= 315ra191 | pmid=26606970 | doi=10.1126/scitranslmed.aad3231 | pmc=4876606 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26606970 }} </ref> Transcriptome analysis of CD3-positive T cells from primates during acute GvHD has led to the | *Regarding prevention, studies have shown that []Aurora kinase]] may be a targetable pathway to prevent GvHD.<ref name="pmid26606970">{{cite journal| author=Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S et al.| title=Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. | journal=Sci Transl Med | year= 2015 | volume= 7 | issue= 315 | pages= 315ra191 | pmid=26606970 | doi=10.1126/scitranslmed.aad3231 | pmc=4876606 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26606970 }} </ref> [[Transcriptome]] analysis of CD3-positive T cells from primates during acute GvHD has led to the discovery that [[Aurora kinase]] is a druggable target. [[Aurora kinase]] inhibitors are available and may be applied to GvHD if future data continues to be promising.<ref name="pmid26606970">{{cite journal| author=Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S et al.| title=Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. | journal=Sci Transl Med | year= 2015 | volume= 7 | issue= 315 | pages= 315ra191 | pmid=26606970 | doi=10.1126/scitranslmed.aad3231 | pmc=4876606 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26606970 }} </ref> Additional preventive strategies include optimization of the graft-versus-tumor and GvHD balance in favor of a graft-versus-tumor effect. This balance might be achieved by manipulating [[regulatory T cells]] or [[NKT]] cells.<ref name="pmid21892378">{{cite journal| author=Patel SA, Rameshwar P| title=Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells. | journal=Curr Pharmacogenomics Person Med | year= 2011 | volume= 9 | issue= 3 | pages= 229-239 | pmid=21892378 | doi=10.2174/187569211796957548 | pmc=3164538 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21892378 }} </ref> | ||
*Regarding diagnostics, early and more sensitive diagnostic strategies are being studied. Wireless capsule endoscopy has been proposed for upper GI GvHD diagnosis.<ref name="pmid25360304">{{cite journal| author=Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T et al.| title=Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. | journal=United European Gastroenterol J | year= 2014 | volume= 2 | issue= 3 | pages= 206-15 | pmid=25360304 | doi=10.1177/2050640614529283 | pmc=4212456 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25360304 }} </ref> A pilot study of 15 patients showed that wireless capsule endoscopy could be a novel method for early GI GvHD diagnosis. The benefits are that this procedure is less invasive that a traditional endoscopy and bypasses the potential problem of false negatives, given patchy distribution of inflammation in GI GvHD.<ref name="pmid25360304">{{cite journal| author=Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T et al.| title=Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. | journal=United European Gastroenterol J | year= 2014 | volume= 2 | issue= 3 | pages= 206-15 | pmid=25360304 | doi=10.1177/2050640614529283 | pmc=4212456 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25360304 }} </ref> | *Regarding diagnostics, early and more sensitive diagnostic strategies are being studied. [[Wireless capsule endoscopy]] has been proposed for upper GI GvHD diagnosis.<ref name="pmid25360304">{{cite journal| author=Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T et al.| title=Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. | journal=United European Gastroenterol J | year= 2014 | volume= 2 | issue= 3 | pages= 206-15 | pmid=25360304 | doi=10.1177/2050640614529283 | pmc=4212456 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25360304 }} </ref> A pilot study of 15 patients showed that [[wireless capsule endoscopy]] could be a novel method for early GI GvHD diagnosis. The benefits are that this procedure is less invasive that a traditional endoscopy and bypasses the potential problem of false negatives, given patchy distribution of inflammation in GI GvHD.<ref name="pmid25360304">{{cite journal| author=Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T et al.| title=Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study. | journal=United European Gastroenterol J | year= 2014 | volume= 2 | issue= 3 | pages= 206-15 | pmid=25360304 | doi=10.1177/2050640614529283 | pmc=4212456 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25360304 }} </ref> | ||
*Regarding therapeutics, there are a few medications that are currently being investigated for GvHD treatment. Such examples include ibrutinib (a Bruton's tyrosine kinase inhibitor) and ruxolitinib (a JAK2 inhibitor). These medications are not formally FDA-approved thus far, but they may become approved in the near future pending further clinical studies. | *Regarding therapeutics, there are a few medications that are currently being investigated for GvHD treatment. Such examples include [[ibrutinib]] (a Bruton's tyrosine kinase inhibitor) and ruxolitinib (a JAK2 inhibitor). These medications are not formally FDA-approved thus far, but they may become approved in the near future pending further clinical studies. | ||
There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention<ref>http://www.clinicaltrial.gov/ct2/results?term=Graft-versus-host+disease search of clinicaltrials.gov for Graft-versus-host disease]</ref>. | There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention<ref>http://www.clinicaltrial.gov/ct2/results?term=Graft-versus-host+disease search of clinicaltrials.gov for Graft-versus-host disease]</ref>. | ||
Revision as of 20:35, 22 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease future or investigational therapies |
|
FDA on Graft-versus-host disease future or investigational therapies |
|
CDC on Graft-versus-host disease future or investigational therapies |
|
Graft-versus-host disease future or investigational therapies in the news |
|
Blogs on Graft-versus-host disease future or investigational therapies |
|
Risk calculators and risk factors for Graft-versus-host disease future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
There are a few new investigational efforts in place for GvHD prevention, diagnostics, and therapeutics.
Future or Investigational Therapies
- Regarding prevention, studies have shown that []Aurora kinase]] may be a targetable pathway to prevent GvHD.[1] Transcriptome analysis of CD3-positive T cells from primates during acute GvHD has led to the discovery that Aurora kinase is a druggable target. Aurora kinase inhibitors are available and may be applied to GvHD if future data continues to be promising.[1] Additional preventive strategies include optimization of the graft-versus-tumor and GvHD balance in favor of a graft-versus-tumor effect. This balance might be achieved by manipulating regulatory T cells or NKT cells.[2]
- Regarding diagnostics, early and more sensitive diagnostic strategies are being studied. Wireless capsule endoscopy has been proposed for upper GI GvHD diagnosis.[3] A pilot study of 15 patients showed that wireless capsule endoscopy could be a novel method for early GI GvHD diagnosis. The benefits are that this procedure is less invasive that a traditional endoscopy and bypasses the potential problem of false negatives, given patchy distribution of inflammation in GI GvHD.[3]
- Regarding therapeutics, there are a few medications that are currently being investigated for GvHD treatment. Such examples include ibrutinib (a Bruton's tyrosine kinase inhibitor) and ruxolitinib (a JAK2 inhibitor). These medications are not formally FDA-approved thus far, but they may become approved in the near future pending further clinical studies.
There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention[4].
References
- ↑ 1.0 1.1 Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S; et al. (2015). "Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention". Sci Transl Med. 7 (315): 315ra191. doi:10.1126/scitranslmed.aad3231. PMC 4876606. PMID 26606970.
- ↑ Patel SA, Rameshwar P (2011). "Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells". Curr Pharmacogenomics Person Med. 9 (3): 229–239. doi:10.2174/187569211796957548. PMC 3164538. PMID 21892378.
- ↑ 3.0 3.1 Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T; et al. (2014). "Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study". United European Gastroenterol J. 2 (3): 206–15. doi:10.1177/2050640614529283. PMC 4212456. PMID 25360304.
- ↑ http://www.clinicaltrial.gov/ct2/results?term=Graft-versus-host+disease search of clinicaltrials.gov for Graft-versus-host disease]